<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD06230000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q96RI1</UniProt_ID>
  <Seq_Length>486</Seq_Length>
  <Molecule_Weight>55914</Molecule_Weight>
  <KEGG_ID>hsa:9971</KEGG_ID>
  <Orthology_ID>K08537</Orthology_ID>
  <Function_Summary>Ligand-activated transcription factor. Receptor for bile acids such as chenodeoxycholic acid, lithocholic acid and deoxycholic acid. Represses the transcription of the cholesterol 7-alpha-hydroxylase gene (CYP7A1) through the induction of NR0B2 or FGF19 expression, via two distinct mechanisms. Activates the intestinal bile acid-binding protein (IBABP). Activates the transcription of bile salt export pump ABCB11 by directly recruiting histone methyltransferase CARM1 to this locus.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>4</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>RXR-interacting protein 14</Alias>
      <Alias>Farnesoid X-activated receptor</Alias>
      <Alias>Retinoid X receptor-interacting protein 14</Alias>
      <Alias>Farnesol receptor HRR-1</Alias>
      <Alias>Nuclear receptor subfamily 1 group H member 4</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently, in a ligand dependent manner, with a nuclear receptor protein.</Detail>
      <Keyword>Ligand-dependent nuclear receptor binding</Keyword>
      <Ontology_ID>GO:0016922</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a activating transcription factor and also with the basal transcription machinery in order to increase the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between activating transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription coactivator activity</Keyword>
      <Ontology_ID>GO:0003713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Functions to initiate or regulate RNA polymerase II transcription by binding an enhancer region of DNA.</Detail>
      <Keyword>Sequence-specific enhancer binding RNA polymerase II transcription factor activity</Keyword>
      <Ontology_ID>GO:0003705</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a repressing transcription factor and also with the basal transcription machinery in order to stop, prevent, or reduce the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between repressive transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription corepressor activity</Keyword>
      <Ontology_ID>GO:0003714</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a RNA polymerase II (Pol II) enhancer. In mammalian cells, enhancers are distal sequences that increase the utilization of some promoters, and can function in either orientation and in any location (upstream or downstream) relative to the core promoter.</Detail>
      <Keyword>RNA polymerase II enhancer sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0000980</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Protein that positively regulates either the transcription of one or more genes, or the translation of mRNA.</Detail>
      <Keyword>Activator</Keyword>
      <Ontology_ID>KW-0010</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with bile acids, any of a group of steroid carboxylic acids occurring in bile.</Detail>
      <Keyword>Bile acid binding</Keyword>
      <Ontology_ID>GO:0032052</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with thyroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Thyroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0004887</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Protein which interferes with transcription, usually by binding to specific sites on DNA. Also used for proteins which repress translation.</Detail>
      <Keyword>Repressor</Keyword>
      <Ontology_ID>KW-0678</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acid stimulus.</Detail>
      <Keyword>Cellular response to acid</Keyword>
      <Ontology_ID>GO:0071229</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving urea.</Detail>
      <Keyword>Regulation of urea metabolic process</Keyword>
      <Ontology_ID>GO:0034255</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of glutamate metabolic process.</Detail>
      <Keyword>Positive regulation of glutamate metabolic process</Keyword>
      <Ontology_ID>GO:2000213</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving bile acids, any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.</Detail>
      <Keyword>Bile acid metabolic process</Keyword>
      <Ontology_ID>GO:0008206</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of bile acids.</Detail>
      <Keyword>Regulation of bile acid biosynthetic process</Keyword>
      <Ontology_ID>GO:0070857</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A transcription regulation process in which the presence of one nitrogen source leads to an increase in the frequency, rate, or extent of transcription, from an RNA polymerase II promoter, of specific genes involved in the metabolism of other nitrogen sources.</Detail>
      <Keyword>Nitrogen catabolite activation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0001080</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency, or extent of cholesterol metabolism, the chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.</Detail>
      <Keyword>Regulation of cholesterol metabolic process</Keyword>
      <Ontology_ID>GO:0090181</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQNLEVEPYSQYSNVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTKKPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCVMDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEGRDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLILTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSDLLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEKLQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLCEIWDVQ</Protein_Seq>
    <DNA_Seq>TCTATGTTTATATCATTTAGCAGGGAAGGATTGTTAATGACTAATCTGTGTCCATGAGGCACAGAGCCAAGGAAGAGATGCTGCTGCTAGCCCAGAAGGCCGCCTGTGATCATGCACAGTACACTGGAACTCTCTCCTCCTCCTCACCTCATTGTCTCCCCGACTTATCCTAATGCGAAATTGGATTCTGAGCATTTGTAGCAAAATCGCTGGGATCTGGAGAGGAAGACTCAGTCCAGAATCCTCCCAGGGCCTTGAAAGTCCATCTCTGACCCAAAACAATCCAAACTTTAGCTCTGTCGTCCAGGCTGGAATGCAGTGGCATGATCAGAGTTCACTGCAGCCTCGACCTCCCAGGCTCAAGTGATCCTCCTGCTTCAACTTCCCAAGTAGCTTGGCTGGGACTACAGGTGTGCATCACCATGCCCAGCTAATTTTTAAATTTTTATTAGAGGGAGGTAGAAGACATCGTAGAAGGAGTGAAAGAAGAAAAGAAGACTTAGAAACATAGCTCAAAGTGAACACTGCTTCTCTTAGTTTCCTGGATTTCTTCTGGACATTTCCTCAAGATGAAACTTCAGACACTTTGGAGTTTTTTTTGAAGACCACCATAAAGAAAGTGCATTTCAATTGAAAAATTTGGATGGGATCAAAAATGAATCTCATTGAACATTCCCATTTACCTACCACAGATGAATTTTCTTTTTCTGAAAATTTATTTGGTGTTTTAACAGAACAAGTGGCAGGTCCTCTGGGACAGAACCTGGAAGTGGAACCATACTCGCAATACAGCAATGTTCAGTTTCCCCAAGTTCAACCACAGATTTCCTCGTCATCCTATTATTCCAACCTGGGTTTCTACCCCCAGCAGCCTGAAGAGTGGTACTCTCCTGGAATATATGAACTCAGGCGTATGCCAGCTGAGACTCTCTACCAGGGAGAAACTGAGGTAGCAGAGATGCCTGTAACAAAGAAGCCCCGCATGGGCGCGTCAGCAGGGAGGATCAAAGGGGATGAGCTGTGTGTTGTTTGTGGAGACAGAGCCTCTGGATACCACTATAATGCACTGACCTGTGAGGGGTGTAAAGGTTTCTTCAGGAGAAGCATTACCAAAAACGCTGTGTACAAGTGTAAAAACGGGGGCAACTGTGTGATGGATATGTACATGCGAAGAAAGTGTCAAGAGTGTCGACTAAGGAAATGCAAAGAGATGGGAATGTTGGCTGAATGTATGTATACAGGCTTGTTAACTGAAATTCAGTGTAAATCTAAGCGACTGAGAAAAAATGTGAAGCAGCATGCAGATCAGACCGTGAATGAAGACAGTGAAGGTCGTGACTTGCGACAAGTGACCTCGACAACAAAGTCATGCAGGGAGAAAACTGAACTCACCCCAGATCAACAGACTCTTCTACATTTTATTATGGATTCATATAACAAACAGAGGATGCCTCAGGAAATAACAAATAAAATTTTAAAAGAAGAATTCAGTGCAGAAGAAAATTTTCTCATTTTGACGGAAATGGCAACCAATCATGTACAGGTTCTTGTAGAATTCACAAAAAAGCTACCAGGATTTCAGACTTTGGACCATGAAGACCAGATTGCTTTGCTGAAAGGGTCTGCGGTTGAAGCTATGTTCCTTCGTTCAGCTGAGATTTTCAATAAGAAACTTCCGTCTGGGCATTCTGACCTATTGGAAGAAAGAATTCGAAATAGTGGTATCTCTGATGAATATATAACACCTATGTTTAGTTTTTATAAAAGTATTGGGGAACTGAAAATGACTCAAGAGGAGTATGCTCTGCTTACAGCAATTGTTATCCTGTCTCCAGATAGACAATACATAAAGGATAGAGAGGCAGTAGAGAAGCTTCAGGAGCCACTTCTTGATGTGCTACAAAAGTTGTGTAAGATTCACCAGCCTGAAAATCCTCAACACTTTGCCTGTCTCCTGGGTCGCCTGACTGAATTACGGACATTCAATCATCACCACGCTGAGATGCTGATGTCATGGAGAGTAAACGACCACAAGTTTACCCCACTTCTCTGTGAAATCTGGGACGTGCAGTGATGGGGATTACAGGGGAGGGGTCTAGCTCCTTTTTCTCTCTCATATTAATCTGATGTATAACTTTCCTTTATTTCACTTGTACCCAGTTTCACTCAAGAAATCTTGATGAATATTTATGTTGTAATTACATGTGTAACTTCCACAACTGTAAATATTGGGCTAGATAGAACAACTTTCTCTACATTGTGTTTTAAAAGGCTCCAGGGAATCCTGCATTCTAATTGGCAAGCCCTGTTTGCCTAATTAAATTGATTGTTACTTCAATTCTATCTGTTGAACTAGGGAAAATCTCATTTTGCTCATCTTACCATATTGCATATATTTTATTAAAGAGTTGTATTCAATCTTGGCAATAAAGCAAACATAATGGCAACAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear euchromatin</CellLocal>
      <Ontology_ID>GO:0005719</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>NR1H4</Gene_Name>
    <Gene_Alias>BAR; FXR; HRR1; RIP14</Gene_Alias>
    <Gene_ID>9971</Gene_ID>
    <Genbank_ACCN>NM_001206977</Genbank_ACCN>
    <Protein_ACCN>NP_001193906</Protein_ACCN>
    <HGNC_ID>7967</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/9971</Gene_URL>
    <UCSC_ID>uc001tht.2</UCSC_ID>
    <EMBL_ID>ENSG00000012504</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Cholestasis, Intrahepatic, of Pregnancy, 1</Disease_Name>
      <Disease_Detail>Cholestasis</Disease_Detail>
      <Disease_DB>CHL116</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cholestasis_intrahepatic_of_pregnancy_1?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atherosclerosis</Disease_Name>
      <Disease_Detail>Atherosclerosis</Disease_Detail>
      <Disease_DB>ATH003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atherosclerosis?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Xanthomatosis</Disease_Name>
      <Disease_Detail>Xanthomatosis</Disease_Detail>
      <Disease_DB>XNT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/xanthomatosis?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intrahepatic Cholestasis</Disease_Name>
      <Disease_Detail>Intrahepatic Cholestasis</Disease_Detail>
      <Disease_DB>INT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intrahepatic_cholestasis?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Biliary Tract Disease</Disease_Name>
      <Disease_Detail>Biliary Tract Disease</Disease_Detail>
      <Disease_DB>BLR006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/biliary_tract_disease?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atp8b1 Deficiency</Disease_Name>
      <Disease_Detail>Atp8b1 Deficiency</Disease_Detail>
      <Disease_DB>ATP014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atp8b1_deficiency?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cholestasis</Disease_Name>
      <Disease_Detail>Cholestasis</Disease_Detail>
      <Disease_DB>CHL068</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cholestasis?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fragile X Syndrome</Disease_Name>
      <Disease_Detail>Fragile X Syndrome</Disease_Detail>
      <Disease_DB>FRG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fragile_x_syndrome?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cerebrotendinous Xanthomatosis</Disease_Name>
      <Disease_Detail>Cerebrotendinous Xanthomatosis</Disease_Detail>
      <Disease_DB>CRB011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cerebrotendinous_xanthomatosis?search=NR1H4#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intrahepatic Cholestasis of Pregnancy</Disease_Name>
      <Disease_Detail>Intrahepatic Cholestasis of Pregnancy</Disease_Detail>
      <Disease_DB>INT099</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intrahepatic_cholestasis_of_pregnancy?search=NR1H4#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide</PDB_Title>
      <PDB_ID>3OMK</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OMK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of a novel class of benzimidazole-based farnesoid X receptor   (FXR) agonists to improve physicochemical and ADME properties</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1H-benzimidazole-6-carboxylic acid</PDB_Title>
      <PDB_ID>3OKH</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OKH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia &amp; diabetes</PubMed_Title>
      <Author>Richter, H.G.F., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)21:191-194</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21134747?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR with SRC1 and GSK359</PDB_Title>
      <PDB_ID>3RUT</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RUT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene.</PubMed_Title>
      <Author>Akwabi-Ameyaw, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:6154-6160</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21890356?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A Chemical, Genetic, and Structural Analysis of the nuclear bile acid receptor FXR</PDB_Title>
      <PDB_ID>1OSH</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OSH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR</PubMed_Title>
      <Author>Downes, M., et al.</Author>
      <Journal>Mol.Cell(2003)11:1079-1092</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12718892?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR with SRC1 and GSK088</PDB_Title>
      <PDB_ID>3HC6</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HC6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>FXR agonist activity of conformationally constrained analogs of GW 4064.</PubMed_Title>
      <Author>Akwabi-Ameyaw, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:4733-4739</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19586769?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Complex Structure of FXR Ligand-binding domain with a tetrahydroazepinoindole compound</PDB_Title>
      <PDB_ID>3L1B</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L1B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Improvement of Physiochemical Properties of the Tetrahydroazepinoindole Series of Farnesoid X Receptor (FXR) Agonists: Beneficial Modulation of Lipids in Primates.</PubMed_Title>
      <Author>Lundquist, J.T., et al.</Author>
      <Journal>J.Med.Chem.(2010)53:1774-1787</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20095622?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human FXR in complex with MFA-1 and co-activator peptide</PDB_Title>
      <PDB_ID>3BEJ</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BEJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation.</PubMed_Title>
      <Author>Soisson, S.M., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2008)105:5337-5342</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18391212?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR bound to isoquinolinecarboxylic acid</PDB_Title>
      <PDB_ID>3P88</PDB_ID>
      <Resolution>2.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P88</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene.</PubMed_Title>
      <Author>Bass, J.Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:1206-1213</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21256005?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide</PDB_Title>
      <PDB_ID>3OKI</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OKI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia &amp; diabetes</PubMed_Title>
      <Author>Richter, H.G.F., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)21:191-194</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21134747?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR with SRC1 and GW4064</PDB_Title>
      <PDB_ID>3DCT</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DCT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.</PubMed_Title>
      <Author>Akwabi-Ameyaw, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:4339-4343</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18621523?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR with SRC1 and GSK8062</PDB_Title>
      <PDB_ID>3DCU</PDB_ID>
      <Resolution>2.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DCU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.</PubMed_Title>
      <Author>Akwabi-Ameyaw, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:4339-4343</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18621523?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>isoxazole ligand bound to farnesoid X receptor (FXR)</PDB_Title>
      <PDB_ID>3GD2</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GD2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.</PubMed_Title>
      <Author>Bass, J.Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2969-2973</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19410460?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR with SRC1 and GSK237</PDB_Title>
      <PDB_ID>3RUU</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RUU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene.</PubMed_Title>
      <Author>Akwabi-Ameyaw, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:6154-6160</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21890356?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid</PDB_Title>
      <PDB_ID>3OOK</PDB_ID>
      <Resolution>2.29</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OOK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of a novel class of benzimidazole-based farnesoid X receptor   (FXR) agonists to improve physicochemical and ADME properties</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>FXR with SRC1 and GSK826</PDB_Title>
      <PDB_ID>3HC5</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HC5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>FXR agonist activity of conformationally constrained analogs of GW 4064.</PubMed_Title>
      <Author>Akwabi-Ameyaw, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:4733-4739</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19586769?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR bound to a quinolinecarboxylic acid</PDB_Title>
      <PDB_ID>3P89</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P89</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene.</PubMed_Title>
      <Author>Bass, J.Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:1206-1213</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21256005?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FXR with SRC1 and GSK2034</PDB_Title>
      <PDB_ID>3RVF</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RVF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene.</PubMed_Title>
      <Author>Akwabi-Ameyaw, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:6154-6160</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21890356?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid</PDB_Title>
      <PDB_ID>3OMM</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OMM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of a novel class of benzimidazole-based farnesoid X receptor   (FXR) agonists to improve physicochemical and ADME properties</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid</PDB_Title>
      <PDB_ID>3OOF</PDB_ID>
      <Resolution>2.29</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OOF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of a novel class of benzimidazole-based farnesoid X receptor   (FXR) agonists to improve physicochemical and ADME properties</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid</PDB_Title>
      <PDB_ID>3OLF</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OLF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of a novel class of benzimidazole-based farnesoid X receptor   (FXR) agonists to improve physicochemical and ADME properties</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Discovery of XL335, a Highly Potent, Selective and Orally-Active Agonist of the Farnesoid X Receptor (FXR)</PDB_Title>
      <PDB_ID>3FLI</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FLI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).</PubMed_Title>
      <Author>Flatt, B., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:904-907</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19159286?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist</PDB_Title>
      <PDB_ID>3FXV</PDB_ID>
      <Resolution>2.26</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FXV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist</PubMed_Title>
      <Author>Feng, S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2595-2598</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19328688?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04976</Pathway_ID>
      <Pathway_Title>Bile secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04976</Pathway_ID>
      <Pathway_Title>Bile secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.de.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1osh</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD06232001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06232002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06232003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06232004</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>